Want to see IBIO full AI Analyst Report?
IBIO Stock Chart & Stats
$2.06
-$0.02(-0.74%)
At close: 4:00 PM EST
$2.06
-$0.02(-0.74%)
Day’s Range― - ―
52-Week Range$0.56 - $3.82
Previous CloseN/A
Volume55.53K
Average Volume (3M)933.86K
Market Cap
$71.04M
Enterprise Value$154.77
Total Cash (Recent Filing)$74.80M
Total Debt (Recent Filing)$2.33M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Sep 29, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding49,678,562
10 Day Avg. Volume774,928
30 Day Avg. Volume933,855
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.54
Price to Sales (P/S)20.03
P/FCF Ratio-0.52
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.67Price Target Upside175.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.31
Revenue Forecast (FY)$100.00K
Bulls Say, Bears Say
Bulls Say
Low Leverage And Meaningful Equity BaseVery low debt relative to equity provides structural financial flexibility, reducing near-term refinancing risk and interest burden. A sizable equity base offers a cushion to fund R&D and supports strategic options (partnerships, licensing) over the next several months without immediate solvency pressure.
Advancing To First-in-human Trial (IBIO-600)Regulatory clearance to start a Phase 1 for IBIO-600 is a durable operational inflection: it shifts a program from preclinical risk to clinical development, enables milestone-driven partnering/licensing, and creates multi-month catalysts tied to trial execution and data generation that can materially de-risk the program.
Promising Preclinical IBIO-610 Obesity DataRobust, durable biomarker suppression and favorable body-composition results suggest a differentiated, long-acting mechanism with combination potential versus GLP-1s. This strengthens strategic partnering and out-licensing prospects and supports sustained clinical development planning over the medium term.
Bears Say
Minimal Revenue And Large Operating LossesOperating results show the company is not yet generating meaningful product revenue and is reporting substantial, persistent losses. This fundamental operating deficit implies the business cannot self-fund development from operations and must rely on external capital or partners to sustain pipeline advancement over the coming months.
Sustained Negative Cash FlowContinued free cash flow burn at sizeable levels materially shortens financial runway absent new funding or material non-dilutive receipts. Persistent negative cash generation constrains timing of trials and partner negotiations and increases execution risk for programs during the next 2–6 months.
Reliance On External Funding And Dilution RiskBecause operations are loss-making and cash negative, the company must access external capital to execute programs. This structural dependency raises dilution risk and can limit strategic flexibility, potentially delaying programs or altering commercial plans if partner deals or financing terms are unfavorable.
Ibio News
IBIO FAQ
What was Ibio Inc’s price range in the past 12 months?
Ibio Inc lowest stock price was $0.56 and its highest was $3.82 in the past 12 months.
What is Ibio Inc’s market cap?
Ibio Inc’s market cap is $71.04M.
When is Ibio Inc’s upcoming earnings report date?
Ibio Inc’s upcoming earnings report date is Sep 29, 2026 which is in 66 days.
How were Ibio Inc’s earnings last quarter?
Ibio Inc released its earnings results on May 12, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.063 by -$0.007.
Is Ibio Inc overvalued?
According to Wall Street analysts Ibio Inc’s price is currently Undervalued.
Does Ibio Inc pay dividends?
Ibio Inc does not currently pay dividends.
What is Ibio Inc’s EPS estimate?
Ibio Inc’s EPS estimate is -0.06.
How many shares outstanding does Ibio Inc have?
Ibio Inc has 49,678,562 shares outstanding.
What happened to Ibio Inc’s price movement after its last earnings report?
Ibio Inc reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.063. Following the earnings report the stock price went down -3.727%.
Which hedge fund is a major shareholder of Ibio Inc?
Currently, no hedge funds are holding shares in IBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ibio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.67 (175.08% Upside)
$5.67 (175.08% Upside)
Blogger Sentiment
Bullish
IBIO Sentiment 70%
Sector Average 65%
Sector Average 65%
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days <0.1%
Last 30 Days <0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
84.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
349.32%
Trailing 12-Months
Company Description
Ibio Inc
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
IBIO Stock 12 Month Forecast
Average Price Target
$5.67
▲(175.08% Upside)
Technical Analysis
Minerva Neurosciences
―
Pulmatrix
―
Chemomab Therapeutics
―
Aspire Biopharma Holdings
―
FibroBiologics, Inc.
―
Ownership Overview
0.61% Insiders
2.62% Mutual Funds
<0.01% Other Institutional Investors
92.43% Public Companies and
Individual Investors